(IXJ) Global Healthcare - Overview

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642873255

Etf: Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Providers

Total Rating 31
Risk 68
Buy Signal -0.73
Risk 5d forecast
Volatility 15.5%
Relative Tail Risk -0.42%
Reward TTM
Sharpe Ratio 0.24
Alpha -5.81
Character TTM
Beta 0.415
Beta Downside 0.372
Drawdowns 3y
Max DD 18.14%
CAGR/Max DD 0.44

Description: IXJ Global Healthcare March 04, 2026

IXJ is an Exchange Traded Fund (ETF) that primarily invests in global healthcare companies. The fund allocates at least 80% of its assets to securities within its underlying index, which tracks the performance of healthcare sector companies deemed important to global markets. The healthcare sector is characterized by a diverse range of businesses including pharmaceuticals, biotechnology, medical devices, and healthcare services.

Up to 20% of IXJs assets may be held in futures, options, swap contracts, cash, and cash equivalents. This allows for flexibility in managing the fund and potentially hedging against market fluctuations. Understanding the specific companies and their business models within this ETF can provide deeper insights. Further research on ValueRay can offer detailed analytics on IXJs holdings and their individual performance.

Headlines to watch out for

  • Global pharmaceutical sales growth impacts healthcare sector revenue
  • Medical device innovation drives industry expansion
  • Healthcare policy changes introduce regulatory risks
  • Aging global population increases demand for medical services

What is the price of IXJ shares?

As of March 13, 2026, the stock is trading at USD 96.30 with a total of 95,275 shares traded.
Over the past week, the price has changed by -2.37%, over one month by -5.35%, over three months by -1.62% and over the past year by +5.97%.

Is IXJ a buy, sell or hold?

Global Healthcare has no consensus analysts rating.

What are the forecasts/targets for the IXJ price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -